Heart inflammation rates higher after Moderna COVID-19 vaccine

(Reuters) -Canadian health officials said on Friday data suggests reported cases of rare heart inflammation were relatively higher after Moderna (NASDAQ:)’s COVID-19 vaccine compared with the Pfizer/BioNTech shots.

The data also indicated heart inflammation occurs more often in adolescents and adults under 30 years of age, and more often in males.

The statement from the Public Health Agency of Canada said majority of the affected individuals experienced relatively mild illness and recovered quickly.

The risk of cardiac complications, including heart inflammation, has been shown to be substantially increased following COVID-19 infections, with the risks higher after the infection than after vaccination, according to the statement.

The benefits of mRNA shots in preventing COVID-19 continue to outweigh the risks, regulators in the United States, EU and the World Health Organization have said.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.